Pharmaron Beijing Co (FRA:17Q1) Cyclically Adjusted PS Ratio: (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:17Q1 Pharmaron Beijing Co Ltd FRA:17Q1
74 GF Score
Price €3.10
GF Value €2.54
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Pharmaron Beijing Co Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Pharmaron Beijing Co  (FRA:17Q1) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Pharmaron Beijing Co Cyclically Adjusted PS Ratio Related Terms


Pharmaron Beijing Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Pharmaron Beijing Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmaron Beijing Co Cyclically Adjusted PS Ratio Chart

Pharmaron Beijing Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 8.10 6.56 6.61

Pharmaron Beijing Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 6.61 0.00 0.00

FRA:17Q1 vs VRTX, REGN, MRNA: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Pharmaron Beijing Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmaron Beijing Co Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pharmaron Beijing Co's Cyclically Adjusted PS Ratio falls into.


FRA:17Q1
74GF Score
Pharmaron Beijing Co Ltd FRA:17Q1
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmaron Beijing Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Pharmaron Beijing Co's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec25 is calculated as:

For example, Pharmaron Beijing Co's adjusted Revenue per Share data for the fiscal year that ended in Dec25 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=0.965/115.8323*115.8323
=0.965

Current CPI (Dec25) = 115.8323.

Pharmaron Beijing Co Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201612 0.197 102.600 0.222
201712 0.221 104.500 0.245
201812 0.279 106.500 0.303
201912 0.324 111.200 0.337
202012 0.362 111.500 0.376
202112 0.568 113.108 0.582
202212 0.783 115.116 0.788
202312 0.835 114.781 0.843
202412 0.908 114.893 0.915
202512 0.965 115.832 0.965

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Pharmaron Beijing Co (FRA:17Q1) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued. The current stock price of €3.10 is trading 22% above its estimated GF Value™ of €2.54. GuruFocus considers Pharmaron Beijing Co to be Modestly Overvalued.

Key valuation signals for FRA:17Q1:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €2.54 vs. price of €3.10 (22% above fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the FRA:17Q1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharmaron Beijing Co Business Description

Other Exchanges 03759:Hong Kong300759:China
Address 6 Tai-He Road, 8th Floor, Block 1, Beijing Economic Technological Development Area, Beijing, CHN, 100176
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
74GF Score

Get the complete analysis for FRA:17Q1

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.10
Price
€2.54
GF Value